131 related articles for article (PubMed ID: 2793386)
21. [Carcinoid tumor--diagnostic and therapeutic problems].
Batowski S; Bielewicz A
Pol Tyg Lek; 1994 Jun 6-13; 49(23-24):536-7. PubMed ID: 7675710
[TBL] [Abstract][Full Text] [Related]
22. Resolution of musculoskeletal symptoms in the carcinoid syndrome after treatment with the somatostatin analog octreotide.
Smith S; Anthony L; Roberts LJ; Oates JA; Pincus T
Ann Intern Med; 1990 Jan; 112(1):66-8. PubMed ID: 2293820
[No Abstract] [Full Text] [Related]
23. Octreotide treatment of carcinoid hypertensive crisis.
Warner RR; Mani S; Profeta J; Grunstein E
Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
[TBL] [Abstract][Full Text] [Related]
24. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
25. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue.
Altman AR; Tschen JA; Rice L
Arch Dermatol; 1989 Mar; 125(3):394-6. PubMed ID: 2923448
[TBL] [Abstract][Full Text] [Related]
26. [Analogs of somatostatin and carcinoid tumors].
Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
[No Abstract] [Full Text] [Related]
27. Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management.
Vinik AI; Thompson N; Eckhauser F; Moattari AR
Acta Oncol; 1989; 28(3):389-402. PubMed ID: 2663049
[TBL] [Abstract][Full Text] [Related]
28. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
van Houten AA; Nortier JW; Vendrik CP
Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
[No Abstract] [Full Text] [Related]
29. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour N; Sawh SC
Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
[TBL] [Abstract][Full Text] [Related]
30. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide.
Pavlovic M; Saiag P; Lotz JP; Marinho E; Clerici T; Izrael V
Arch Dermatol; 1995 Oct; 131(10):1207-9. PubMed ID: 7574845
[No Abstract] [Full Text] [Related]
31. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
33. mTOR inhibitor therapy for patients with carcinoid.
Rindi G; Caplin M
Lancet; 2011 Dec; 378(9808):1978-1980. PubMed ID: 22119494
[No Abstract] [Full Text] [Related]
34. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
35. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
36. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
37. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group.
Arnold R; Benning R; Neuhaus C; Rolwage M; Trautmann ME
Digestion; 1993; 54 Suppl 1():72-5. PubMed ID: 8359572
[TBL] [Abstract][Full Text] [Related]
38. [Update on the anesthetic management of patients with malignant carcinoid syndrome].
Rodríguez-Cosmen C; Trillo Urrutia L; Pacreu Terradas S; Comps Vicente O; Escolano Villén F
Rev Esp Anestesiol Reanim; 2005 May; 52(5):291-4. PubMed ID: 15968907
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of carcinoid syndrome with a somatostatin analogue].
Döbrönte Z; Stöckert A; Végh G; Varga L
Orv Hetil; 1992 Mar; 133(12):731-4. PubMed ID: 1372969
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment.
Gregor M
Digestion; 1994; 55 Suppl 3():60-3. PubMed ID: 7698539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
